MedImmune wins $90M swine flu vax contract

MedImmune has received a $90 million order from the U.S. government for a live attenuated vaccine that can be used against the H1N1 outbreak. The vaccine developer says this could be the first of many new orders for a swine flu jab. And the company, the biotech arm of AstraZeneca, says it will begin shipping the first of 10 million doses of its seasonal flu vaccine in August. Report

Suggested Articles

Pillar is bankrolling a new accelerator for budding biotechs. Petri aims to serve biotech startups at the “frontier of biology and engineering.”

One of the last major, late-stage attempt at stopping Alzheimer’s using a BACE inhibitor has ended up on the trash pile with so many others.

The oligosaccharide microbiome modulator was no better than placebo at reducing lactose intolerance symptoms.